Vancomycin-Associated Nephrotoxicity: The Obesity Factor
- 1 September 2015
- journal article
- research article
- Published by SAGE Publications in Surgical Infections
- Vol. 16 (6) , 684-693
Abstract
Background: Current recommendations suggest that vancomycin dosing utilize actual rather than ideal body weight in obese patients. Thus, obese patients may be at greater risk for nephrotoxicity. The purpose of this study was to compare the incidence of nephrotoxicity in vancomycin-treated obese and lean patients at our institution, where unadjusted, actual body weight-based dosing (capped at 2 g per dose twice daily) is used. We expected obese patients to experience a greater incidence of nephrotoxicity than lean patients. Methods: This study examined a retrospective cohort of patients treated with vancomycin for gram-positive or mixed infections in our facility from 2005–2009 who were not receiving hemodialysis at the time of admission. Patients were stratified by body mass index (BMI; obese ≥30 kg/m 2 vs. lean 21 was the only variable associated with nephrotoxicity (p=0.039). After adjusting for statistically significant variables, obesity was found not to be associated with a greater risk of nephrotoxicity (RR=0.98; 95% CI=0.93–1.04; p=0.59). Conclusion: No difference in nephrotoxicity was observed between lean and obese patients treated with vancomycin at our institution.Keywords
This publication has 46 references indexed in Scilit:
- Determining vancomycin clearance in an overweight and obese populationAmerican Journal of Health-System Pharmacy, 2011
- Vancomycin Dosing in Obese Pediatric PatientsClinical Pediatrics, 2011
- Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatmentDiabetology & Metabolic Syndrome, 2010
- Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?The American Journal of Medicine, 2010
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care settingAmerican Journal of Infection Control, 2008
- Multicenter Evaluation of Vancomycin Dosing: Emphasis on ObesityThe American Journal of Medicine, 2008
- Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of NephrotoxicityAntimicrobial Agents and Chemotherapy, 2008
- Protective Effects of Caffeic Acid Phenethyl Ester, Vitamin C, Vitamin E and N‐Acetylcysteine on Vancomycin‐Induced Nephrotoxicity in RatsBasic & Clinical Pharmacology & Toxicology, 2007
- Studies of renal injury III: Lipid-induced nephropathy in type II diabetesKidney International, 2000
- Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal diseaseKidney International, 1999